GRFS (Grifols) Shares Outstanding (EOP): 681 Mil (As of Mar. 2026)


GRFS Grifols SA GRFS
84 GF Score
Price $7.36
GF Value $8.79
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Grifols Shares Outstanding (EOP)?

Grifols GRFS +2.08% 84 Shares Outstanding (EOP) is 681 Mil as of Mar. 2026. GuruFocus rates GRFS with a GF Score™ of 84/100 and a GF Value™ of $8.79 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Grifols's shares outstanding for the quarter that ended in Mar. 2026 was 681 Mil.

Grifols's quarterly shares outstanding stayed the same from Dec. 2025 (681 Mil) to Mar. 2026 (681 Mil).

Grifols's annual shares outstanding increased from Dec. 2024 (680 Mil) to Dec. 2025 (681 Mil). It means Grifols issued new shares from Dec. 2024 to Dec. 2025 .


Grifols  (NAS:GRFS) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Grifols Shares Outstanding (EOP) Related Terms


Grifols Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Grifols's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols Shares Outstanding (EOP) Chart

Grifols Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 678.54 678.41 679.09 680.41 680.58

Grifols Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 680.41 679.73 680.51 680.58 680.58

GRFS vs LLY, JNJ, ABBV: Shares Outstanding (EOP) Comparison

For the Drug Manufacturers - General subindustry, Grifols's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols Shares Outstanding (EOP) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Grifols's Shares Outstanding (EOP) falls into.


GRFS
84GF Score
Grifols SA GRFS
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grifols Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 681 Mil mean?
Grifols (GRFS) has a Shares Outstanding (EOP) of 681 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Grifols and its competitors.
Is Grifols' Shares Outstanding (EOP) too high?
Grifols' current Shares Outstanding (EOP) is 681 Mil. Overall, Grifols has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' Shares Outstanding (EOP) compare to LLY and JNJ?
Grifols' Shares Outstanding (EOP) of 681 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Drug Manufacturers company?
A good Shares Outstanding (EOP) depends on the Drug Manufacturers industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Grifols and its competitors. Grifols's current Shares Outstanding (EOP) is 681 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.79, compared to a current price of $7.36 — trading 16.3% below its estimated fair value. The current Shares Outstanding (EOP) is 681 Mil. Grifols' overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Grifols (GRFS), the current Shares Outstanding (EOP) is 681 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grifols (GRFS) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of $7.36 is trading 16.3% below its estimated GF Value™ of $8.79. GuruFocus considers Grifols to be Modestly Undervalued.

Key valuation signals for GRFS:

  • Shares Outstanding (EOP): 681 Mil
  • GF Value™: $8.79 vs. price of $7.36 (16.3% below fair value)
  • GF Score™: 84/100 with 6 warning signs

No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
84GF Score

Get the complete analysis for GRFS

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.36
Price
$8.79
GF Value